Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
Study sponsor: Grace Therapeutics Inc. · GRCE
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-12Estimated
Enrollment · participants100Estimated
Source updated2024-10-01Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.